Viracta Therapeutics Inc logo

Viracta Therapeutics Inc Share Price (NASDAQ: VIRX)

▲

-0.08

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 4 Feb 2025

Check the interactive Viracta Therapeutics Inc Stock chart to analyse performance

Viracta Therapeutics Inc Key Stats

Check Viracta Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.0778
Open
$0.0695
Market Capitalization
$3.1M
Today's Volume
$1.9M
Revenue TTM
$0.0
EBITDA
$-49.0M
Earnings Per Share (EPS)
$-1.1
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-208.67%

Global Institutional Holdings in Viracta Therapeutics Inc

  • Name

    Holdings %

  • Citadel Advisors Llc

    3.83%

  • Vanguard Group Inc

    2.40%

  • Samsara BioCapital, LLC

    1.74%

  • Stonepine Capital Management Llc

    1.26%

  • LAURION CAPITAL MANAGEMENT LP

    0.84%

  • Aisling Capital Management LP

    0.73%

Analyst Recommendation on Viracta Therapeutics Inc Stock

Rating
Trend

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Viracta Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Viracta Therapeutics Inc

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Organization
Viracta Therapeutics Inc
Employees
40
CEO
Mr. Mark Andrew Rothera
Industry
Miscellaneous

Key Management of Viracta Therapeutics Inc

NameTitle
Mr. Mark Andrew Rothera
CEO, President & Director
Dr. Darrel P. Cohen M.D., Ph.D.
Chief Medical Officer
Dr. Susan Perrine M.D.
Scientific Founder and Consultant
Dr. Ronald J. Berenson M.D.
Co-Founder and Consultant
Mr. George Hillman
Co-Founder
Dr. Thalia Papayannopoulou M.D.
Co-Founder
Dr. Robert M. Williams Ph.D.
Co-Founder
Dr. Douglas V. Faller M.D., Ph.D.
Scientific Founder & Chairman of Scientific Advisory Board
Mr. Michael Eric Faerm
Chief Financial Officer
Dr. Ayman El-Guindy
Chief Scientific Officer

Important FAQs about investing in VIRX Stock from India :

What is Viracta Therapeutics Inc share price today?

Viracta Therapeutics Inc share price today is as on . Viracta Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Viracta Therapeutics Inc share?

Viracta Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Viracta Therapeutics Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Viracta Therapeutics Inc Stock (VIRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Viracta Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viracta Therapeutics Inc Shares .

What is the minimum amount required to buy Viracta Therapeutics Inc Stock (VIRX) from India?

Indian investors can start investing in Viracta Therapeutics Inc (VIRX) shares with as little as ₹89.9525 or $1 (as of January 08, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹899.52 in Viracta Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on January 08, 2026). Learn more about fractional shares .

What are the returns that Viracta Therapeutics Inc has given to Indian investors in the last 5 years?

Viracta Therapeutics Inc stock has given 0.0% share price returns and 22.99% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?